A notable example is the analysis of the STOMP-like and ORIOLE trial cohorts, in which circulating PSMA-positive extracellular vesicles (PSMA+ EVs) were shown to be powerful prognostic and predictive biomarkers in oligorecurrent prostate cancer managed with stereotactic ablative radiotherapy (SABR).136. The gene discussed is FOLH1; the disease is prostate carcinoma.